>> he worked with other officials to put together an emergency use authorization or an eua because thestration and leadership was planning to create this broad access to hydroxychloroquine that would essentially give americans access to the drugs on demand. what he was able to negotiate as somewhat of a compromise position is that the drug would only be given in hospitals, to patients who have been diagnosed with covid-19 under the care of a physician. that was what he negotiated as a position, a compromised position to protect people from the effects of the drug. once the eua was in place, leadership and the administration ignored it, violated it, and continued to press forward and decided, for example, as we saw in that email, that they were going to flood new york and new jersey with the drug. so the eua was a compromised position. >> let me ask you finally, is this whistle-blower complaint just the first step to you? do you plan to file a lawsuit? give us a quick status check on where things stand right now? are you in touch with members of congress to bring this issue forward? >>

we authorize one of these eua's. in one of the situation where the patients can't wait for the randomized controlled studies to begin, at times commit as were taking this eua approved medication because the harm is now, the benefit outweighs the harm. that is always the goal with getting a treatment. all medical treatments whether a surgery or medication, there are harms and benefits. the goal is to give a medication and/or a treatment plan more benefits than horns. right now we cannot be certain of that because we don't have randomized controlled results done yet, but we see promise command we see patients that don't have a choice to the benefit and that outweighs the harms. >> neil: doctor, good catching up with you and i appreciate the guidance on this and the significance of this. thank you, be well my friend. i want to go to the anchor, sunday, she and bret baier, turning the work to town hall, virtually with the president of the united states, martha come i would imagine this will be a subject that comes up on

so this eua or this emergency use authorization was expected. i think in the initial part when they trial these types of medications they always trial it on the sickest patients first, jake. i think the question now going forward is to really identify who is likely to most benefit from a medication like this, when to give it, how to give it, all that sort of stuff. >> and we just have the sound in right now from president trump officially making this announcement. let's roll that tape. >> i'm pleased to announce that gilead now has an eua from the fda for remdesivir. and you know what that is because that's been the hot thing also in the papers and in the media for the last little while. an important treatment for hospitalized coronavirus patients. >> now, remdesivir, as we've discussed, it's been found to help patients recover faster, about a third faster, i think, in this early nih trial. right now it can only be used on hospitalized patients. it's delivered from iv, not orally. the ceo said today he hopes it can be used earlier in patients wi

he usesed to pay about 35 5 eua month. now he pays 40. he thinks it's worth it. mzwandlie: actually i am very, very, very happy, because if you are staying in the shack it is not like you are staying in the room. shack is like,e, it is not a ple to be as a human being, actually. to stay in a room is where you feel confident and everything, and shack is not a room. reporter: buililding rubble isa major environmental problem in the impoverished districts of johannesburg. many companies just dump their waste inin the townships to o d papaying disposal fees. nondndumiso sibibiya knows thil too well. every day, dozens of trucks come to her neighborhood to illegally dump building waste from more prosperous areas. this bothered her a lot, until it inspired her to become an entrepreneur. now she's fofounded a start-up that processes waste. nondumiso: a lot of peoplele o waste removal, right? they collect wasaste and then ty collect waste. but then we actually take responsibility of where the waste ends up. we rehabilitate roads with the waste. we compost it. we also o re

i am pleased to announce that gilead now has a eua from the fda for remdesivir, you know what that isn the papers and media for the last little while. an important treatment for hospitalised coronavirus patients, and something i spoke with dr khan and dr fauci, i spoke with deborah about it. it is really a very promising situation. we have been doing work with the teams at the fda, nih and gilead for spearheadhing this private—public partnership to make this happen very quickly. our north america correspondent david willis is following the story. this drug is said to be helping patients suffering coronavirus to recover faster. there was a trial conducted involving about a thousand patients and it showed that those who took the drug recovered, normally it would be about 15 days, pared down to 11 days. that's a 31% difference and it's seen by medical experts here as potentially very significant if for no other reason than the fact that it suggests to them that a drug is capable of blocking this virus. now, it's a modest breakthrough but it is all we have at the moment. it's not a cure,

we announced the positive results of the trial of remdesivir and issued an eua for hospitalized patients with covid-19. two other promising treatments that i mentioned are the antibody-rich products, convalescent plasma and microimmunoglobulin and i am happy to go into more detail if members of this committee have questions about this, but we are working very aggressively and coasting with stakeholders to facilitating to develop the monoclonal antibodies which if shown to be safe and effective -- >> hello, everyone. i want to highlight three critical aspects of president trump's response to the coronavirus that have exceeded the media's expectations and should inspire confidence in every american across this country. rest assured the trump administration is working tirelessly to defeat the invisible enemy. first, contrary to some media pronounce ams the united states did not need the 1 million ventilators thus far that the media said we were in dire need of. in fact, it is encouraging to say that every american who needed a ventilator has received a ventilator. this administration has ma

i am pleased to announce that gilead now has a eua from the fda for remdesivir, you know what that ist has been a hot thing also in the papers and media for the last little while. an important treatment for hospitalised coronavirus patients, and something i spoke with the doctors and deborah about it. it is really a very promising situation. we have been doing work with the teams at the fda, nih and gilead for spearheadhing this private—public partnership to make this happen very quickly. we will be getting more from oui’ correspondence we will be getting more from our correspondence david willis shortly. there are growing reports from the us that the trump administration is formulating a plan to punish china on multiple fronts for the coronavirus pandemic, further damaging a relationship already on a steep downward slide. with an election just six months away, some of the president's critics believe a campaign strategy of blaming beijing is emerging, to divert attention from president trump's handling of the crisis. danny russel is the vice—president at the asia society policy instit

iam i am pleased to announce that it now has a eua from the fda for remdesivir, you know what that is a hot thing also in the papers and media for the last little while. an important treatment for hospitalized coronavirus patients and something i spoke with the doctors and deborah about it. it is really a promising situation. we have been doing work with the teams at the fda, nih and gilead for this private public partnership to make this happen very quickly. doctor lina wen, served as health commissioner for the city of baltimore. she explains why the green light to use remdesivir is important. it is really significant that we at least have something in our tool box to treat this disease but we have to remember what it is good for. so far remdesivir is only studied in the use remdesivir is only studied in the use of extremely ill hospitalized patients and it reduces their recovery time which is important that this is not a cure. this is not a vaccine, it is not a way to prevent getting covid—19 so we have to keep up the measurement, and other measures like social distancing to stop g

iam i am pleased to announce that gary had now has an eua from the fda for remdesivir. that has been the hot thing also in the paper and has been the hot thing also in the paperand in has been the hot thing also in the paper and in the media for the paper and in the media for the last little while. important treatment for hospitalized coronavirus patients and it is something that i spoke with the doctors and deborah about it and it is really a very promising situation. we have been doing work with the teams at the fda, nih and gilead for this public— private sponsorship to get under way. 0ur north america correspondent david willis joins us live. it is not a vaccine or a year, it seems to be a useful treatment? that is right, it is a antiviral drug and unlike antibiotic, it does not destroy the target pathogen but stops the target pathogen but stops the pathogen from spreading. in tests of 1000 patients and the us government revealed earlier this week that it had shown quite significant effects. of those 1000 patients, the virus and the spread of the virus was slowed an

accuracy was sacrificed at expense of speed, fda spokesperson told us fda oversight doesn't end with an eua. emergency use authorization. we will continue to track the tests and take action ifbeen ta for a listening time. not getting the infection is the ultimate goal. protect yourself. in the white house now they are getting tested every day. that might be too many tests. every day maybe too frequently. actually doing everything to slow down the spread within the white house people wearing masks. that's something we have to see. with regard to the test themselves, there's a lot of people in the public health community that say the fda needs to be making sure these tests are accurate and validated. as you heard, a bad test can be worse than no test at all. >> thank you very much. hispanic communities across the country hit hard by coronavirus. both by the virus itself and the economic repercussions. we'll get the stories behind the numbers. whoo-hoo! great tasting ensure with 9 grams of protein, 27 vitamins and minerals, and nutrients to support immune health. and nutrients to i don't have

. >> i'm pleased to announce that gilead has eua from the fda from remdesivir, an important treatmentfor hospitalized coronavirus patients. it's really a promising situation. arthel: that is president trump praising preliminary results on remdesivir as the fda issues an emergency approval for the drug to treat covid-19. this after a clinical trial showed it shortened recovery times in some of the most severely ill patients with the virus. joining me now peter pitts, former fda associate commissioner and also president and cofounder of center for medicine in the public interest. good to have you here and want to jump right in, peter. how historic is this move, this emergency approval and what's the likelihood of success of remdesivir as covid-19 treatment? peter: well, remdesivir doesn't get emergency approval, got emergency use authorization which means that it didn't quite meet the approval standards, but considering the crisis that we are in, the benefit that the drug has within a certain patient population allows patients to free up patients as they see fit, serious manifestations

. >> bret: i'm pleased to announce that gilead now has an eua from the fda.at that is because that's been the hot thing also in the papers. >> i think this illustrates what can happen in such a short time. from the first case that was diagnosed in the united states to now, our first step forward was therapeutic and less than 90 days for those of us and viral diseases and pandemics for a long time, this is our first really positive step forward. >> it's not a vaccine, but it is a treatment, and it is approved by the fda. back with the panel, charles, susan, and bill mcgurn, columnist for "the wall street journal." bill, this is a step, obviously, they are really trying to do this at warp speed to getting a vaccine. and millions and millions of vaccines out by next year. >> absolutely, i think that's what we have to hope for. if it's a daunting challenge, because they haven't ever been done before in this kind of time crunch. if >> what about chuck, this development and the big picture. >> big picture, i guess you'd have to say is the first, scientifically docu

sacrificed at the expense of speed, an fda spokesperson told cnn, fda oversight doesn't end with an eua. or emergency-use authorization. we will continue to track these tests and take action, if required. >> so, don, obviously, testing is important. we have been talking about that for a long time. but not getting the infection is still the ultimate goal. so you want to do everything you can to protect yourself. we know, in the white house now, they are getting tested every day. that might, in fact, be too many tests. you know, every day may be too frequently. but, actually, doing everything to slow down the spread within the white house, people wearing masks, i mean, i think that's something that we're going to have to see. now, with regard to the tests, themselves, there is a lot of people in the public-health community that say the fda needs to be making sure these tests are accurate. that they're validated before they go out there because, as you heard, don, a bad test can be worse than no test at all. don. >> dr. gupta, thank you very much. >>> hispanic communities across the countr

we announced the positive results of the trial of remdesivir and issued an eua for hospitalized patients with covid-19. two other promising treatments that i mentioned are the antibody-rich products, convalescent plasma and microimmunoglobulin and i am happy to go into more detail if members of this committee have questions about this, but we are working very aggressively and coasting with stakeholders to facilitating to develop the monoclonal antibodies which if shown to be safe and effective -- >> hello, everyone. i want to highlight three critical aspects of president trump's response to the coronavirus that have exceeded the media's expectations and should inspire confidence in every american across this country. rest assured the trump administration is working tirelessly to defeat the invisible enemy. f,

. >> i am pleased to announce eua from the fda of remdesivir.hat has been in the media, important treatment for hospitalized patients. it is something, i spoke with dr. khan and dr. fauci. i spoke with deborah about it. it is a promising situation. from the oval office earlier today. jenny is next from lancaster, ohio. caller: i have trouble expressing myself. bestl try to say this as as i can. does china use more of their natural herbs and things on their country more than what we use? do they use the medicine we use in the united states, or do they use their natural medicines more? anybodywould work, has gone into what the chinese use? steve: thank you. dr. saag: it is a good question. even in the united states we have a lot of folks who use natural herbs and other remedies to treat different disorders. i am confident that happens in china. china uses what we call western or traditional medicines as well. fromines originally came .atural products, bark that is how we came up with a lot of antibiotics like penicillin. the take-home point is we

. >> reporter: when asked if accuracy was important, fda oversight doesn't end with an eua or emergency use authorization. we will continue to track these tests and take action if required. >> our thanks to dr. gupta for that. >>> former president obama says the rule of law is at risk. why the michael flynn case is sparking new outcry next live in the cnn newsroom. state farm is announcing the good neighbor relief program we're returning $2 billion dollars to our auto policyholders through may 31st. because now, more than ever, being a good neighbor means everything. like a good neighbor, state farm is there. and you may have a lot on your mind. we want to help, with real questions from you, and real answers from experts. we can get through this together. visit letsbreathetogether.com. >>> a crime cannot be established here. they did not have a basis for a counterintelligence investigation against flynn at that stage. >> when history looks back on this decision, how do you think it will be written? >> well, history is written by the winners so it largely depends on who is writing the hi

but, i think this eua or this emergency-use authorization was pretty expected, anderson. >> so, tomorrow, as of tomorrow, there is going to be at least 32 states easing some restrictions. somewhat. to varying degrees. dr. fauci last night told us on our town hall that it was a gamble. how long before we know what the sort of effect of that gamble is in terms of cases? >> yeah. you know, i mean, that's the thing is that typically, because of the way the testing's done right now, people aren't getting tested until they develop symptoms and -- or sometimes not getting tested until they show up in the hospital. so the time period between when someone is exposed to this virus and the time they develop symptoms can vary. but it can be up to a couple weeks, as you know, that is wrae that 14-day incubation period comes from. can be shorter than that. and then if nthey go to the hospital, if could be a week after that. and then sadly, if they die, maybe another week after that. so you're talking when you start to look at the -- the -- the this tragic death count, when it starts to go up, will sor

there's a lot of test that is have not been approved that go away for a little bit until they get the euat does that specific impact have on the overall fight against the pandemic at this stage? >> so, the reason they're doing this, now we know that that antibody test can tell you yes or no or and they're pretty accurate as far as whether you have antibodies. we don't know what that means other than you recover from it. we don't know if that's going to give you life-long immunity or any immunity at all. it's going to be harder to get tests for a little bit and more tests with crop up soon. there's a lot of antibody tests out there. it's one of those things that the general public can look at to see what's happening in a community. as far as people, even if you test positive, you need to take safety measures to make sure everybody else is protected. >> dr. john torres with that check on the news. thanks again. >>> new york putting together an army of contact tracers. the governor says that's going to be key to reopening the state. we're going to talk to the doctor developing that program a

an e-mail followed a week later saying ignore the eua, push this drug into the retail pharmacies in new york and new jersey, that's when i became more concerned. >> who put that directive out? >> gentleman's time is expired. >> you can answer dr. bright. >> which directive? >> should it be put out to the public without physicians approving it? >> that directive was an e-mail string that had a number of individuals. it came from the secretary of health indicated the the white house was asking for that drug. >> was it because the president was encouraged by the use of this drug that you became discouraged by? >> it had nothing to do with politics. i want to make sure americans are aware of this drug. >> it was a drug that indicated and has been used in the past. >> you can finish your answer dr. bright and we are going to move to the next member. >> it was used for malaria. >> gentleman, your time is over. please, please. i am overly generous of both sides of the isle. we need to move on. two-minutes of extra time is two-minutes of extra time. i am not going to ask that it would be shared

sacrificed at the expense of speed, an fda spokesperson told cnn fda oversight doesn't end with an eua or emergency use authorization. we will continue to track these tests and take action if required. >> for those at home, sanjay, why does the quality of tests vary so much? >> i think there was this big rush, jake, to get these tests out there. you know, we know that the original test the cdc put out ended up being flawed, they couldn't validate some of the results. all of a sudden it became this big push and all these test makers put their tests out there. they didn't validate their results ahead of time, they weren't necessarily asked to do that. that was the emergency use authorization. now we're going through thes process of validating those tests. jake, some of these tests being widely used in some situations still have a high false negative rate. we talk a lot about the numbers of tests. until we can make sure the tests we are using are accurate, that may be a more fundamental problem. >> sanjay, president trump just addressed the news that vice president pence's press secretary

we've already produced about 400 of these helmets and as you say, we're in the eua process right nowh the fda hopefully in the next few weeks, that's approved and we're able to get these out here. our long-term future will not be producing medical devices. we're trying to do our part with some great engineering to help folks out in the community and what we would love to do is share that technology with other folks who are in the business so we can get that out, not just domestically, but also internationally. >> yeah, george whiteside, ceo of virgin galactic, thank you for joining us today >> thanks so much, morgan. >> all right, guys dow is down 72 points. obviously, a lot of data came our way this morning we'll get more tomorrow with jobless claims, but tonight we'll have etsy to work with and fox and lyft and paypal and square, as weapon continue to handle all kinds of data points, whether it's labor data, corporate earnings, today it's oil inventories. but a fair amount of chop. let's get to the judge and the half >> carl, thanks so much. our breaking news coverage of the market

this emergency use authorization to flood new york and new jersey with this drug regardless of the eua. when i spoke outside of our government and shared my concerns for the american public, that i believe is the straw that broke the camel's back and escalated my removal. >> thank you. thank you, madam chair. >> the gentleman's time has expired. pleasure to recognize the gentleman from kentucky, mr. guthrie for his five minutes of questions. >> thank you very much. thank you, dr. bright for being here. we appreciate it very much. reading through your complaint, i want to point out, i think the chairman said earlier, talked about the lack of urgency and implies the president's lack of urgency. i think most of my constituents want to know that things are getting done and where is the president on this. you're having issues with that, leadership at health and human services, and you're giving them recommendations. if they're not accepting your recommendations to them, i would i think fairly surmise they're not passing that on to the white house. the president is probably unaware of what y

fauci mentioned, we recently announced the positive results of the trial of remdesivir and issued an euaor the treatment of hospital isised patients with covid-19. two other treatments are the antibody treatments and i'm willing to go into more detail if members of this committee have questions about this. but we are working very aggressively and closely with stakeholders to facilitate the development which if shown to be safe and effective could act as a bridge therapy to the development of a vaccine. we recognize that it needs to go hand in hand with ensuring there will be sufficient supplies for our country. so we're also working with manufacturers to make sure that this supply chain is robust. mr. chairman, ranking members, members of the committee, in the fda, you have a dedicated team of some of the nation's finest scientists and health officials. we are guided by science and data and we facilitate the development of products that our nation needs to get back to work. >> thanks to all four of you for your expertise. we'll now begin a round of five-minute questions from each senator

i'm pleased to announce that gilead now has an eua from the fda for remdesivir. you know what that is because that's been the hot thing also in the papers and in the media for the last little while. an important treatment for hospitalized coronavirus patients. and it's something i spoke with dr. khan and dr. fauci. i spoke with deborah about it, and it's really a very promising situation. we've been doing work with the teams at the fda, nih, and gilead for spearheading this public private partnership to make this happen very quickly. so today we're going to be -- i'm going to let dan do it, but we're going to let dan make a statement as to what the company is doing, making a contribution to really people that are not doing well, people that are sick, people who have this horrible plague that's set into our country, and we're getting rid of, and we're going to be having some really incredible results. we have very promising studies coming out on the vaccines. we have promising studies coming out on therapeutics, and the first one is from dan and gilead. i would li

placee put the eua in which locks the drug down to only be used under close supervision of a sedition -- of a physician we had the guardrails in place. with the email string followed a week later saying to ignore the eua and push this into the retail pharmacies in new york and new jersey. mr. carter: -- who put that directive out. >> the gentleman's time has expired. but you can answer. dr. bright: which directive? mr. carter: that it should be put to the public without physicians? an email string that had a number of individuals on it, i believe it first came from the assistant secretary of health who indicated the white house was asking for that drug to be more broadly used. mr. carter: was it because the president was encouraged by the use of this drug that she became discouraged? dr. bright: nothing to do with politics, i wanted to make sure that americans were aware of the risk of this drug and that it was only available specifically. timet -- the gentleman's has expired by 1.5 minutes. you can finish her answer dr. bright, then we are moving to the next member. dr. bright: it ha

. >> i'm pleased to announce that gilead now has an eua from the fda for remdesivir an important treatmentlized coronavirus patients. it's really a very promising situation. jillian: a break through in the fight against coronavirus. the fda issuing an emergency use authorization for the antiviral therapy remdesivir in treating some patients with covid-19. here to react is fox news medical contributor dr. j net nesheiwat. good to see you, doctor. >> good morning, jillian, good to see you, too. jillian: tell me what you think of the drug. >> this is a very, very significant important finding that we have in this trial of remdesivir. very encouraging. it's going to have a positive impact on the community that it's going to save lives. what it tells us is this drug can stop and block the formation of this virus. and what we're seeing is that patients who are hospitalized they get to leave it four to five days earlier. it's 11 day stay for patients on remdesivir vs. 15 days. 31% improvement they will recover faster. the mortality rate is slightly lower as well. definitely something we need. giv

fauci mentioned, we recently announced the positive results of remdesivir and issued an eua of the treatmentspitalized patients with covid-19. two other promising treatments are the antibody rich products. i am certainly willing to go into more detail if members of the committee have questions about this. we are working aggressively and closely with stake holders to facilitate the development of the antibodies. which if safe and effective, could act as a bridge therapy. we realize this needs to go hand-in-hand for the sufficient supplies for the country. we are working with manufacturers to make sure this is robust. mr. chairman and ranking members of the committee, please know you have the dedicated team of scientists and professionals. we are guided by science and data and we won't let up until we facilitate the development of products that our nation needs to get back to work. i look forward to your questions. >> thank you, dr. hahn and all four of you for your expertise and dedication to our country and hard work. we will begin a round of five-minute questions from each senator. alternat

the emergency use authorization, to flood new york and new jersey with this drug regardless of the eua. when i spoke outside of the government and shared my concern with the american public, that i believe was the straw that broke the camels back and escalated my removal. mr. engel: thank you. thank you, madam chair. >> the gentleman's time has expired. a pleasure to recognize the gentleman from kentucky, mr. guthrie for his five minutes of questions. mr. guthrie: thank you very much. thank you, dr. bright for being here. we appreciate it very much. reading your complaint, i want to point out that the chairman said earlier, i talked about the lack of urgency and implied the president's lack of urgency, most of my constituents want to know that things are getting done and where is the president on this. you are having issues with the leadership at health and human services and you are giving them recommendations. if they are not accepting your i would fairly, surmise that should go to the white house. so the president is unaware what you are putting forth. because reading from your comp

allowing it to be used for five days so that's going to allow them to double the supply the only place the eua course is for intubated patients so patients who have already been put on a ventilator right now, they specify the drug's indicated for patients who have symptoms of covid that causes them to have low oxygen or requires sup mental oxygen so it can be used in moderate patients as well as severe so i think this is a pretty broad indication a pretty broad authorization and gives max mall flexible thety to physicians so it's a very good development. >> it is a good development. and there have been a number of them lately when it comes to other treatments potentially and some clinical trials we've been keeping an eye on. vaccine momentum testing momentum and the numbers continue to improve in this country for hospitalizations deaths icu visits what's your level of optimism would you say heading out at the end of this week versus where you were a few weeks ago >> well i think we need to be cautious what we're seeing nationally if you look at the national trends without the new york data, so

. >> gilead now has an eua from the fda for remdesivir. and you know what that is because that's been the hot thing. >> reporter: regulators allowing emergency use of an experimental drug that could help coronavirus patients recover faster. [ cheers ] >> reporter: protests across the country in areas that are still locked down. >> even if we opened up tomorrow, i don't know how long it would take business to recover. >> reporter: canada has banned assault-style weapons less than two weeks after canada's deadliest rampage. >> canadians deserve more than thoughts and prayers. >> reporter: the new white house press secretary held her first briefing for reporters. the first white house press secretary in more than 400 days. >> i will never lie to you. you have my word. >> reporter: north korea state media says leader kim jong-un has appeared in public for the first time in 20 days. >> reporter: tesla stocks plunged minutes after a tweet from elon musk. >> he tweeted out tesla stock is too high. >>> all that -- >> a bicycle kick by an 8-year-ol

issued an eua for hospitalized patients with covid-19.tments that i mentioned are the antibody-rich products, hyper mun globulin and i'm happy to go into more detail if you have questions about this. stake holders to facilitate, which if shown to be safe and effective could act as a bridge therapy to the development of vaccine. we recognize the developing vaccines and therapies need to go hand in hand, with ensuring there will be sufficient supplies for our companies, for our country. so we're also working with manufacturers to make sure this supply chain is robust. mr. chairman, ranking member, members of the committee, please know in fda you have a dedicated team to some of the nation's finest scientists, health care professionals. we are guided by science and data and we won't let up until we facilitate the products our nation needs to get back to work. i appreciate your questions. >> thank you, dr. hahn. thanks to all four of you for your expertise, your dedication to our country and your hard work. alternating between democrats and r